IL202997A - Isolated cells expressing recombinantly 15-yl and mammalian ralpha 15-yl - Google Patents

Isolated cells expressing recombinantly 15-yl and mammalian ralpha 15-yl

Info

Publication number
IL202997A
IL202997A IL202997A IL20299709A IL202997A IL 202997 A IL202997 A IL 202997A IL 202997 A IL202997 A IL 202997A IL 20299709 A IL20299709 A IL 20299709A IL 202997 A IL202997 A IL 202997A
Authority
IL
Israel
Prior art keywords
15ralpha
isolated cells
recombinantly express
express mammalian
mammalian
Prior art date
Application number
IL202997A
Other languages
English (en)
Hebrew (he)
Other versions
IL202997A0 (en
Original Assignee
Novartis Ag
Us Health
Admune Therapeutics Llc
Marine Polymer Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40186225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL202997(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Us Health, Admune Therapeutics Llc, Marine Polymer Tech Inc filed Critical Novartis Ag
Publication of IL202997A0 publication Critical patent/IL202997A0/en
Publication of IL202997A publication Critical patent/IL202997A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
IL202997A 2007-06-27 2009-12-27 Isolated cells expressing recombinantly 15-yl and mammalian ralpha 15-yl IL202997A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93747107P 2007-06-27 2007-06-27
PCT/US2008/008084 WO2009002562A2 (en) 2007-06-27 2008-06-27 Complexes of il-15 and il-15ralpha and uses thereof

Publications (2)

Publication Number Publication Date
IL202997A0 IL202997A0 (en) 2011-08-01
IL202997A true IL202997A (en) 2017-06-29

Family

ID=40186225

Family Applications (1)

Application Number Title Priority Date Filing Date
IL202997A IL202997A (en) 2007-06-27 2009-12-27 Isolated cells expressing recombinantly 15-yl and mammalian ralpha 15-yl

Country Status (11)

Country Link
US (3) US9931377B2 (enExample)
EP (3) EP2173378B1 (enExample)
JP (7) JP2010531878A (enExample)
AU (1) AU2008269032B2 (enExample)
CA (1) CA2691785C (enExample)
DK (1) DK2173378T3 (enExample)
ES (2) ES2466916T3 (enExample)
HK (1) HK1198421A1 (enExample)
IL (1) IL202997A (enExample)
NZ (4) NZ616254A (enExample)
WO (1) WO2009002562A2 (enExample)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001677A2 (en) 2005-05-17 2007-01-04 University Of Connecticut Compositions and methods for immunomodulation in an organism
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
JP5603012B2 (ja) 2005-12-02 2014-10-08 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用
EP2366787B1 (en) 2006-01-13 2019-12-11 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells
EP2388266B1 (en) 2007-05-11 2014-04-23 Altor BioScience Corporation Fusion molecules and IL-15 variants
EP2173378B1 (en) * 2007-06-27 2014-03-19 Admune Therapeutics LLC Complexes of il-15 and il-15ralpha and uses thereof
WO2011020047A1 (en) 2009-08-14 2011-02-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of il-15 to increase thymic output and to treat lymphopenia
KR20120093163A (ko) * 2009-09-14 2012-08-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｉｌ-15 수용체 알파 및/또는 이를 인코딩하는 핵산 분자를 포함하는 백신 및 면역 치료제, 및 이를 이용하는 방법
CN101837123B (zh) * 2010-05-27 2016-05-25 四川大学 肿瘤细胞疫苗及其制备方法
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
JP6251570B2 (ja) 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
AU2011317211B2 (en) 2010-10-22 2015-04-16 Dana-Farber Cancer Institute, Inc. Discovery of regulatory T cells programmed to suppress an immune response
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US9156897B2 (en) * 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
US10548957B2 (en) 2012-09-28 2020-02-04 Dana-Farber Cancer Institute, Inc. Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritis
US20150359853A1 (en) * 2012-10-24 2015-12-17 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
PE20151921A1 (es) 2013-03-14 2015-12-26 Icahn School Med Mount Sinai Virus de la enfermedad de newcastle y usos de los mismos
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
JP2016518361A (ja) 2013-04-19 2016-06-23 シーチューヌ ファルマＣｙｔｕｎｅ Ｐｈａｒｍａ 血管漏出症候群の発生を抑制するサイトカイン治療
EP2997134B1 (en) * 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
CA2920539C (en) * 2013-08-08 2024-01-02 Cytune Pharma Combined pharmaceutical composition
SI3030575T1 (sl) 2013-08-08 2018-11-30 Cytune Pharma Modulokini na osnovi IL-15 in IL-15R-alfa sushi domene
EP3093295B1 (en) 2014-01-08 2020-05-27 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-15 heterogeneous dimer protein and uses thereof
DK3105335T3 (da) 2014-02-14 2020-01-13 Univ Texas Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
AU2015222685A1 (en) 2014-02-27 2016-09-08 Viralytics Limited Combination method for treatment of cancer
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
CN122399016A (zh) 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
SG10202109752XA (en) 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
CA2953816C (en) 2014-06-30 2022-03-15 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
JP6831777B2 (ja) 2014-07-21 2021-02-17 ノバルティス アーゲー Ｃｄ３３キメラ抗原受容体を使用する癌の処置
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3180359A1 (en) 2014-08-14 2017-06-21 Novartis AG Treatment of cancer using gfr alpha-4 chimeric antigen receptor
EP3712171A1 (en) 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
US10577417B2 (en) 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
US10905743B2 (en) * 2014-12-19 2021-02-02 Jiangsu Hengrui Medicine Co., Ltd. Interleukin 15 protein complex
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
JP2018529753A (ja) 2015-10-06 2018-10-11 ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー 転移性及び難治性癌及び腫瘍の処置のための方法及び組成物
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
SG10201913163PA (en) * 2015-12-18 2020-03-30 Oncosec Medical Inc Plasmid constructs for heterologous protein expression and methods of use
PT3393504T (pt) 2015-12-22 2025-12-30 Novartis Ag Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
SG11201807489PA (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
US20190112380A1 (en) 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
WO2017173367A2 (en) 2016-03-31 2017-10-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extracellular vesicles, methods of making them, and methods of reducing liver uptake of extracellular vesicles
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CA3024509A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
US11365252B2 (en) 2016-07-20 2022-06-21 University Of Utah Research Foundation CD229 CAR T cells and methods of use thereof
CA3032669A1 (en) * 2016-08-01 2018-02-08 William Jia Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
JP7467117B2 (ja) 2016-10-07 2024-04-15 ノバルティス アーゲー 癌の治療のためのキメラ抗原受容体
MX2019004327A (es) 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
MX2019004681A (es) 2016-10-21 2019-10-07 Altor Bioscience Corp Moleculas basadas en il-15 multimericas.
CA3049652A1 (en) 2017-01-10 2018-07-19 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
AU2018227583B2 (en) 2017-03-03 2023-06-01 Obsidian Therapeutics, Inc. CD19 compositions and methods for immunotherapy
US10743996B2 (en) * 2017-03-24 2020-08-18 Robert L. Bundy Amnion putty for cartilage repair
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
AU2018257917B2 (en) * 2017-04-24 2023-05-04 University Of Massachusetts Diagnosis and treatment of vitiligo
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CA3064375A1 (en) 2017-05-25 2018-11-29 Memorial Sloan Kettering Cancer Center Use of the il-15/il-15ra complex in the generation of antigen-specific t cells for adoptive immunotherapy
IL327498A (en) 2017-06-02 2026-05-01 Juno Therapeutics Inc Articles of manufacture and methods for treatment using adoptive cell therapy
CN111050545A (zh) 2017-06-29 2020-04-21 朱诺治疗学股份有限公司 评估与免疫疗法相关的毒性的小鼠模型
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
US11066475B2 (en) 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
MA49911A (fr) 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
EP3724225A1 (en) 2017-12-15 2020-10-21 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
SG11202008261WA (en) * 2018-03-08 2020-09-29 Rubius Therapeutics Inc Therapeutic cell systems and methods for treating cancer and infectious diseases
CA3094329A1 (en) * 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
US11267866B2 (en) 2018-04-04 2022-03-08 Nant Holdings Ip, Llc Immunoglobulin complex comprising interleukin-15
CA3097593A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
CA3097625A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
WO2019204646A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
KR20210003814A (ko) 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
IL279367B2 (en) 2018-06-13 2026-05-01 Novartis Ag BCMA chimeric antigen receptors and their uses
MX2020014290A (es) 2018-06-22 2021-08-05 Cugene Inc Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos.
CN121086085A (zh) 2018-06-22 2025-12-09 科优基因公司 新型白介素-15 (il-15)融合蛋白及其用途
EP3837277A4 (en) 2018-08-17 2022-05-11 Icahn School of Medicine at Mount Sinai RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION
JP7556848B2 (ja) * 2018-09-14 2024-09-26 モデルナティエックス インコーポレイテッド ｍＲＮＡ治療薬を使用したがんを治療するための方法及び組成物
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
WO2020077180A1 (en) 2018-10-11 2020-04-16 Nantcell, Inc. Treatment of immunosuppressed subjects
CA3116188A1 (en) 2018-10-12 2020-04-16 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
US12473345B2 (en) 2018-11-01 2025-11-18 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
CN119569895A (zh) 2018-11-01 2025-03-07 朱诺治疗学股份有限公司 G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体
BR112021009420A2 (pt) 2018-11-16 2021-11-23 Juno Therapeutics Inc Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b
SG11202105422RA (en) * 2018-11-29 2021-06-29 Virogin Biotech Canada Ltd Hsv vector with reduced neurotoxicity
EP4427810A3 (en) 2018-11-30 2024-12-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
US11618776B2 (en) 2018-12-20 2023-04-04 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
EA202192103A1 (ru) 2019-01-29 2021-12-15 Джуно Терапьютикс, Инк. Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1)
WO2020198293A1 (en) * 2019-03-25 2020-10-01 Northshore University Health System Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
IL297147B1 (en) 2020-04-10 2026-05-01 Juno Therapeutics Inc Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen
KR20230107617A (ko) 2020-11-13 2023-07-17 노파르티스 아게 키메라 항원 수용체(car)-발현 세포를 사용한 병용 요법
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
US12234473B2 (en) 2020-12-31 2025-02-25 Immatics US, Inc. CD8 polypeptides, compositions, and methods of using thereof
WO2022204267A1 (en) 2021-03-24 2022-09-29 Alkermes, Inc. Upar antibodies and fusion proteins with the same
JP2025521543A (ja) 2022-06-22 2025-07-10 ジュノー セラピューティクス インコーポレイテッド Ｃｄ１９標的ｃａｒ ｔ細胞のセカンドライン治療のための処置方法
KR20250044344A (ko) 2022-08-04 2025-03-31 노파르티스 파르마 아게 아토피 피부염의 치료에 유용한 il-15 저해제
EP4565262A2 (en) 2022-08-05 2025-06-11 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
US20260048099A1 (en) 2022-08-16 2026-02-19 The United States Of America, As Represented By The Secretary, Deparment Of Health And Human Service Synergistic interactions for improved cancer treatment
US20260207667A1 (en) 2022-12-13 2026-07-23 Juno Therapeutics, Inc. Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
WO2025019869A2 (en) * 2023-07-20 2025-01-23 The Johns Hopkins University Cell culture medium and compositions thereof

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2444713A1 (fr) 1978-12-18 1980-07-18 Pasteur Institut Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
JPS6297624A (ja) 1985-10-24 1987-05-07 イ−・アイ・デユポン・デ・ニモアス・アンド・カンパニ− ガス分離法及びその膜
JPS62205784A (ja) * 1986-03-05 1987-09-10 雪印乳業株式会社 新しい型のプラスミノ−ゲン活性化因子の製造方法
US4705540A (en) 1986-04-17 1987-11-10 E. I. Du Pont De Nemours And Company Polyimide gas separation membranes
US4717394A (en) 1986-10-27 1988-01-05 E. I. Du Pont De Nemours And Company Polyimide gas separation membranes
US4717393A (en) 1986-10-27 1988-01-05 E. I. Du Pont De Nemours And Company Polyimide gas separation membranes
US4912197A (en) 1987-08-14 1990-03-27 E. I. Du Pont De Nemours And Company Highly soluble clear polyimides
US4880442A (en) 1987-12-22 1989-11-14 E. I. Du Pont De Nemours And Company Polyimide gas separation membranes
US4935490A (en) 1988-04-13 1990-06-19 E. I. Dupont De Nemours And Company Highly soluble aromatic polyimides
US4863496A (en) 1988-04-13 1989-09-05 E. I. Du Pont De Nemours And Co. Reactive posttreatment for gas separation membranes
US4851505A (en) 1988-04-13 1989-07-25 E. I. Du Pont De Nemours And Company Highly soluble aromatic polyimides
US4838900A (en) 1988-04-13 1989-06-13 E. I. Du Pont De Nemours And Company Polyimide gas separation membranes
US4961539A (en) 1989-08-01 1990-10-09 Deem K Michael Truck-mounted pallet chipper
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DE4135070C1 (enExample) 1991-10-24 1993-05-19 Institut Fuer Rundfunktechnik Gmbh, 8000 Muenchen, De
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5552303A (en) 1993-03-08 1996-09-03 Immunex Corporation DNA encoding epithelium-derived T-cell factor
US5574138A (en) 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US5686115A (en) 1993-12-01 1997-11-11 Marine Polymer Technologies, Inc. Poly-β-1→4-N-acetylucosamine copolymer composition with collagen
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
US5624679A (en) 1993-12-01 1997-04-29 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine biological barriers
US5622834A (en) 1993-12-01 1997-04-22 Marine Polymer Technologies, Inc. Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture
US5858350A (en) 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
JP3547163B2 (ja) * 1994-03-17 2004-07-28 雪印乳業株式会社 無血清培地を用いた物質生産方法
WO1995027722A1 (en) 1994-04-06 1995-10-19 Immunex Corporation Interleukin-15
US6548065B1 (en) 1994-05-06 2003-04-15 Immunex Corporation Interleukin-15 receptors
US5591630A (en) 1994-05-06 1997-01-07 Immunex Corporation Monoclonal antibodies that bind interleukin-15 receptors
US20020127201A1 (en) 1994-07-01 2002-09-12 Dana-Farber Cancer Institute. Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain
US7008624B1 (en) 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
US5660824A (en) 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
DE19608813C2 (de) 1996-03-07 1998-07-02 Angewandte Gentechnologie Syst Konjugat zur Beeinflussung von Wechselwirkungen zwischen Proteinen
US6451308B1 (en) 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
JP2001502521A (ja) 1996-04-26 2001-02-27 ベス イスラエル デアコネス メディカル センター インターロイキン―１５の拮抗剤
EP0971728B1 (en) 1997-02-21 2002-12-11 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Use of interleukin-15
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US20040170604A1 (en) 1998-07-06 2004-09-02 Tosoh Corporation IL-6 receptor IL-6 direct fusion protein
JP2003525061A (ja) 2000-03-01 2003-08-26 メディミューン，インコーポレイテッド 高効力組換え抗体およびその産生法
US6569681B1 (en) 2000-03-14 2003-05-27 Transkaryotic Therapies, Inc. Methods of improving homologous recombination
WO2001080889A1 (en) 2000-04-26 2001-11-01 National Jewish Medical And Research Center Product and process for regulation of t cell responses
MXPA03002278A (es) 2000-09-14 2004-12-03 Beth Israel Hospital Modulacion de respuestas de la celula t mediadas por il-2 e il-15.
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7041657B2 (en) 2001-02-12 2006-05-09 Marine Polymer Technologies Inc. Compositions and methods for modulation of vascular structure and/or function
US7638604B2 (en) 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
US20030044406A1 (en) 2001-03-02 2003-03-06 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
EP1575509B1 (en) 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
EP1519956B1 (en) 2002-05-10 2011-09-21 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
US8663622B2 (en) 2002-12-16 2014-03-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant vaccine viruses expressing IL-15 and methods using the same
DE10260805A1 (de) 2002-12-23 2004-07-22 Geneart Gmbh Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
AU2004214932B2 (en) 2003-02-24 2009-12-03 Marine Polymer Technologies, Inc. Cell-polymer fiber compositions and use thereof
WO2005023289A1 (ja) 2003-09-08 2005-03-17 Intellectual Property Consulting Incorporated 慢性ｃ型肝炎を治療するための医薬組成物
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
ES2367027T3 (es) 2004-02-27 2011-10-27 Inserm (Institut National De La Santé Et De La Recherche Medicale) Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
US20060057680A1 (en) 2004-08-11 2006-03-16 Zheng Xin X Mutant interleukin-15 polypeptides
US20060104945A1 (en) * 2004-10-05 2006-05-18 Choi Yong S Enhancement of B cell proliferation by IL-15
EP1824964A4 (en) 2004-11-19 2009-04-01 Biogen Idec Inc METHODS FOR PRODUCING MAMMAL CELLS
WO2006063301A1 (en) * 2004-12-10 2006-06-15 Maxcyte, Inc. Genetically modified tumor cells as cancer vaccines
BRPI0607351A2 (pt) 2005-02-15 2009-09-01 Novartis Vaccines & Diagnostic métodos para tratamento de linfomas empregando uma combinação de agente quimioterapêutico e il-2 e opcionalmente um anticorpo anti-cd20
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
WO2007001677A2 (en) 2005-05-17 2007-01-04 University Of Connecticut Compositions and methods for immunomodulation in an organism
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
WO2007070488A2 (en) 2005-12-12 2007-06-21 The Cbr Institute For Biomedical Research, Inc. Integrin alpha l i domain mutants with increased binding affinity
US20070160578A1 (en) 2005-12-14 2007-07-12 The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
EP2366787B1 (en) 2006-01-13 2019-12-11 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells
AU2007214426A1 (en) 2006-02-16 2007-08-23 Nascent Biologics, Inc. Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject
US8586055B2 (en) 2007-01-12 2013-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services DNA immunization protocols
EP2388266B1 (en) 2007-05-11 2014-04-23 Altor BioScience Corporation Fusion molecules and IL-15 variants
EP2173378B1 (en) 2007-06-27 2014-03-19 Admune Therapeutics LLC Complexes of il-15 and il-15ralpha and uses thereof
WO2011020047A1 (en) 2009-08-14 2011-02-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of il-15 to increase thymic output and to treat lymphopenia
JP6251570B2 (ja) 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines

Also Published As

Publication number Publication date
CA2691785A1 (en) 2008-12-31
US11110150B2 (en) 2021-09-07
HK1198421A1 (en) 2015-04-24
WO2009002562A2 (en) 2008-12-31
CA2691785C (en) 2017-01-10
JP2014114294A (ja) 2014-06-26
ES2716476T3 (es) 2019-06-12
NZ599338A (en) 2013-11-29
HK1143084A1 (en) 2010-12-24
AU2008269032B2 (en) 2013-12-05
AU2008269032A1 (en) 2008-12-31
US20110081311A1 (en) 2011-04-07
US20190290734A1 (en) 2019-09-26
EP2724728B1 (en) 2018-10-17
US10265382B2 (en) 2019-04-23
NZ616254A (en) 2015-04-24
NZ582330A (en) 2012-05-25
US9931377B2 (en) 2018-04-03
EP2173378A2 (en) 2010-04-14
JP2010531878A (ja) 2010-09-30
ES2466916T3 (es) 2014-06-11
JP2021152017A (ja) 2021-09-30
JP2017079745A (ja) 2017-05-18
IL202997A0 (en) 2011-08-01
JP2015212270A (ja) 2015-11-26
EP2724727A1 (en) 2014-04-30
WO2009002562A3 (en) 2009-02-26
NZ703668A (en) 2016-07-29
JP2019088288A (ja) 2019-06-13
EP2173378A4 (en) 2010-09-29
JP2023015158A (ja) 2023-01-31
US20170151310A1 (en) 2017-06-01
EP2173378B1 (en) 2014-03-19
EP2724728A1 (en) 2014-04-30
DK2173378T3 (da) 2014-05-12

Similar Documents

Publication Publication Date Title
IL261851B (en) Reprogramming of t cells and hematopoietic cells
IL221384A0 (en) Improving il-15 and il-15r-alpha for expression in mammalian cells
EP2405452A4 (en) ELECTRODE MATERIAL AND ELECTRODE WITH ELECTRODE MATERIAL
IL225740A0 (en) Adapted factor vii polypeptides and uses thereof
ZA201004736B (en) Improved mammalian expression vectors and uses thereof
IL200012A0 (en) Anti-robo4 antibodies and uses therefor
EP2262038A4 (en) Cell selector and cell with it
ZA201004899B (en) Biological materials and uses thereof
EP2461821A4 (en) MODIFIED POLYPEPTIDES OF FACTOR IX AND USES THEREOF
GB0812087D0 (en) Receptacle and support
GB0708376D0 (en) Novel polypeptides and uses thereof
GB0904825D0 (en) Biological materials and uses thereof
EP2227540A4 (en) DIFFERENTIATION OF HUMAN CELLS
PL2406280T3 (pl) Materiały biologiczne oraz ich zastosowania
PT2233560T (pt) Dispositivo de cultura de células ou tecidos e conjunto associado
GB0811362D0 (en) Biological materials and uses thereof
TWI373159B (en) Electrolyte for electrochemical device and the electrochemical device thereof
TWI370215B (en) Supporting member and bulb with the supporting member
GB0922143D0 (en) Biological materials and uses thereof
EP2185685A4 (en) NEW PROCESSES AND NEW CELL LINES
GB0802980D0 (en) Biological materials and uses thereof
GB0819324D0 (en) Improved reprogramming of mammalian cells, and the cells obtained
GB0805508D0 (en) Improved reprogramming of mammalian cells, and the cells obtained
GB0802501D0 (en) Improved reprogramming of mammalian cells, and the cells obtained
GB0909244D0 (en) Novel Photo-voltaic and electrochemical material

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed